Physician’s Weekly – 02/09/2022 – For a study, researchers sought to examine the combined efficacy results from a phase Ib regorafenib plus nivolumab (REGONIVO) study and a phase II lenvatinib plus pembrolizumab (LENPEM) trial in advanced gastric cancer (AGC) with or without liver metastases (REGONIVO plus LENPEM cohort). Additionally, they looked into the effectiveness of anti-PD-1 monotherapies (anti-PD-1 monotherapy cohort). Using multiplex IHC, the immune microenvironments of original gastric tumors and liver metastases were also contrasted. In the REGONIVO plus LENPEM cohort with a median follow-up of 14.0 months, the objective response rate (ORR), median progression-free survival (mPFS), and median overall survival (mOS) for patients with liver metastases were, respectively, 46%, 7.8 months, and 15.6 months, compared to 69%, 6.9 months, and 15.5 months for those without. At a median follow-up of 27.6 months in the anti-PD-1 monotherapy cohort, patients with liver metastases had ORR, mPFS, and mOS of 9%, 1.4 months, and 6.4 months, respectively, compared to those without, who had ORR, 2.3 months, and 9.0 months. Compared to primary gastric tumors, liver metastases had fewer CD8+ T cells and more immune-suppressive cells, such as tumor-associated macrophages and regulatory T cells. Despite a more immunosuppressive tumor microenvironment in liver metastases, anti-PD-1 antibodies in combination with regorafenib or lenvatinib for AGC demonstrated a positive anticancer effect with a longer follow-up.
Originally Published By Physician’s Weekly. Reused by Medicom Medical Publishers with permission.
©2022 Physician’s Weekly. All rights reserved. No works may be reproduced without expressed written consent from Physician’s Weekly. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by Physician’s Weekly.
« Efficacy of Pembrolizumab Chemotherapy in Gastric Cancer and Tumor Mutational Burden Next Article
Trastuzumab-deruxtecan Potential Second-line Therapy Option in HER2-Positive Gastric Cancer »
HER2-expressing metastatic colorectal cancer: trastuzumab deruxtecan